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Weight loss due to negative energy balance is a goal in counteracting obesity and
type 2 diabetes mellitus. The thyroid is known to be an important regulator of energy
metabolism through the action of thyroid hormones (THs). The classic, active TH,
3,5,3′-triiodo-L-thyronine (T3) acts predominantly by binding to nuclear receptors termed
TH receptors (TRs), that recognize TH response elements (TREs) on the DNA, and
so regulate transcription. T3 also acts through “non-genomic” pathways that do not
necessarily involve TRs. Lipid-lowering therapies have been suggested to have potential
benefits, however, the establishment of comprehensive therapeutic strategies is still
awaited. One drawback of using T3 in counteracting obesity has been the occurrence of
heart rhythm disturbances. These are mediated through one TR, termed TRα. The end of
the previous century saw the exploration of TH mimetics that specifically bind to TR beta
in order to prevent cardiac disturbances, and TH derivatives such as 3,5-diiodo-L-thyronine
(T2), that possess interesting biological activities. Several TH derivatives and functional
analogs have low affinity for the TRs, and are suggested to act predominantly through
non-genomic pathways. All this has opened new perspectives in thyroid physiology
and TH derivative usage as anti-obesity therapies. This review addresses the pros and
cons of these compounds, in light of their effects on energy balance regulation and on
lipid/cholesterol metabolism.
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INTRODUCTION
The thyroid plays a crucial role in the control of energy
metabolism through action of thyroid hormones (THs) in
metabolically active tissues such as liver, skeletal muscle and
brown adipose tissue. Knowledge on TH action has increased
significantly after the cloning of the TH receptors (TRs) termed
TRα (including splice-variants α1 and α2 of which α2 does not
bind to TH) and TRβ (including transcripts β1 and β2, with
β1 predominantly involved in metabolic control, see for a more
detailed review: Mullur et al., 2014). TRα1 (henceforth: TRα) is
expressed in the brain and to a lesser extent in kidney, skele-
tal muscle, lungs, heart, and liver, whereas TRβ1 (henceforth:
TRβ) is expressed predominantly in the kidneys and liver, and
at lower levels in brain, heart, thyroid, skeletal muscle, lungs,
and spleen (Williams, 2000). In absence of hormone, transcrip-
tional regulation through the TRs is blocked through association
with co-repressors (Astapova and Hollenberg, 2013). An exam-
ple comes from a recent study reporting expression of an inactive
mutant of nuclear receptor co-repressor (NCoR), NCoRID, in
mouse liver which, by favoring coactivator recruitment and recep-
tor activation, resulted in increased expression of genes encoding
enzymes involved in bile acid metabolism that are under tran-
scriptional control of TRβ (Astapova et al., 2014). Interestingly,
one coactivator of TRβ has been recently discovered to be a sir-
tuin, namely SIRT1 (Singh et al., 2013; Suh et al., 2013; Thakran
et al., 2013). To exert their action, TRs commonly heterodimerize
with the retinoic X receptor (RXR) but may also homodimerize
(Forman et al., 1992). In addition, TRs interact with other nuclear
receptors including peroxisome proliferator activated receptors
(PPARs), (Bogazzi et al., 1994; Buroker et al., 2007; de Lange
et al., 2007). TR-PPAR interactions are of particular importance
in regulation of lipid metabolism. The in vivo association of
unliganded TRα with PPARα has been shown to inhibit PPARα
signaling in the liver, a process abolished by T3 (Liu et al.,
2007). A dominant negative TRα mutant associated with PPARα
in a way that could not be abolished by T3, resulting in hep-
atic steatosis (Liu et al., 2007). Thus, these results imply that
T3 “unblocks” PPARα action by relieving TRα association with
PPARα. In accordance, TRα knock-out mice were shown to be
protected from diet-induced hepatic insulin resistance (Jornayvaz
et al., 2012). TRβ isoforms reduce serum lipids in vivo (Johansson
et al., 2005; Angelin and Rudling, 2010; Pramfalk et al., 2011;
Shoemaker et al., 2012). TRβ disruption in mice has been shown
to impair fatty acid oxidation (Araki et al., 2009) which per-
sisted with TRα overexpression (Gullberg et al., 2000, 2002). This
implies that T3 increases lipid metabolism both by binding to
TRα and TRβ and through PPARs, however through different
underlying mechanisms. Physical interactions between TRβ and
PPARα in mouse heart (Buroker et al., 2007), and PPARδ in
rat skeletal muscle (de Lange et al., 2007) have been suggested
to increase expression of common target genes involved in lipid
metabolism.
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THE DEVELOPMENT OF SPECIFIC TRβ AGONISTS AS
LIPID/CHOLESTEROL-LOWERING AGENTS
Hyperthyroidism can lead to thyrotoxicosis, with increased heart
rate, atrial arrhythmias and heart failure, muscle wasting, post-
menopausal osteoporosis in women, fatigue, anxiety, and prefer-
ence for decreased temperatures (Webb, 2004). Basic studies have
revealed that TRα is responsible for TH’s effects on heart rate:
mice lacking TRα showed reduced heart rate and body tempera-
ture (Wikström et al., 1998), and echocardiograph studies in mice
deficient in TRα or TRβ have revealed that the effects of THs on
heart rate are TRα-dependent (Weiss et al., 2002). Cardiac con-
tractile functions and the expression of genes involved therein
have been shown to be all TRα-dependent (Gloss et al., 2001).
Initial studies on TH analogs date from before the cloning
of the TRs and showed that analogs binding strongly to hep-
atic TRs but weakly to heart TRs (Ichikawa et al., 2000) were
effective in reducing body weight and serum lipid/cholesterol lev-
els but did not cause evident cardiac arrhythmias. L-94901, the
first described selective thyromimetic compound with 50% of the
binding affinity of T3 to hepatic TRs and only a minimal affin-
ity to cardiac TRs (Underwood et al., 1986), has been reported to
lower plasma cholesterol in experimental animals without induc-
ing cardiotoxic side effects. A subsequent compound, CGS 23425,
lowered total serum and LDL cholesterol and increased synthe-
sis of apolipoprotein A1 (APOA1). Indeed, after the cloning of
the TRs, CGS 23425 was confirmed to be weakly TRβ-selective
(Taylor et al., 1997).
Because of TRα-associated unwanted side effects of TH, the
nineties saw the development of TRβ-specific ligands [these
comprise GC-1 (Chiellini et al., 1998), its derivative GC-24
(Borngraeber et al., 2003), and KB141 (Grover et al., 2005)],
or, alternatively, ligands targeted to the liver. The first such
cholesterol-reducing compound with high liver specificity was
CGH-509A (derived from conjugation of L-T3 and cholic acid).
Other drugs developed for targeting to the liver wereMB-07811, a
prodrug of the active metaboliteMB07344 (Erion et al., 2007) and
KB-2115 (Berkenstam et al., 2008). Several compounds that were
intentionally designed to be liver-specific were subsequently also
found to be TRβ-selective, and vice versa. For instance, the selec-
tive TRβ-agonist GC-1 has been found to be preferentially taken
up by the liver (Baxter and Webb, 2009) and, in turn, MB-07811
resulted to be more than ten-fold TRβ-selective. TRβ affinity
varies between compounds: GC-1 (Chiellini et al., 1998) has equal
TRβ affinity with respect to T3, GC-24 (Borngraeber et al., 2003)
andMB-07344 (Erion et al., 2007; Fujitaki et al., 2008) have a rela-
tive twofold-lower affinity, and KB-141 has a sixfold lower relative
affinity (Erion et al., 2007). In addition, the synthetic agonists
have different pharmacokinetic and pharmacodynamics proper-
ties with respect to T3 (Erion et al., 2007). Finally, effective tissue
uptake differs between the compounds, which could be related
to their relative affinities for the classic TH transporters such as
monocarboxylate transporter-8 (MCT-8) (Erion et al., 2007).
TH ANALOGS AND CHOLESTEROL METABOLISM
A large number of TH analogs ameliorate lipid and lipoprotein
metabolism through the lowering of plasma total and LDL choles-
terol levels and the stimulation of reverse cholesterol transport
(RCT) in different animal models (Baxter and Webb, 2009;
Tancevski et al., 2009; Pramfalk et al., 2011). The LDL cholesterol-
lowering effect exerted by TRβ1- and liver-selective thyromimet-
ics such as KB-141, GC-1, KB-2115, MB-07811, T-0681, CGS-
23425, and DITPA (Underwood et al., 1986; Taylor et al., 1997;
Grover et al., 2003, 2004; Erion et al., 2007; Tancevski et al., 2009)
is ascribed to increased hepatic LDL clearance via stimulation of
LDL receptor (Erion et al., 2007; Tancevski et al., 2009, 2010)
and the stimulation of cholesterol 7 alpha-hydroxylase (CYP7A1)
expression and activity (Gullberg et al., 2000; Johansson et al.,
2005; Erion et al., 2007; Tancevski et al., 2010) enhancing hepatic
cholesterol uptake and its conversion into bile acids to be excreted
by feces. Moreover, T0681 induces the expression of ABCG5 and
ABCG8, a tandem pump promoting the biliary excretion of free
cholesterol (Tancevski et al., 2010). Recent mechanistic studies in
mice showed the LDL receptor (LDLr) expression to be crucial
for the hypocholesterolemic effects of MB-07811 and for T-0681
(Erion et al., 2007; Tancevski et al., 2010) which was not the case
for that of T3, GC-1 and KB-2115 (Goldberg et al., 2012; Lin
et al., 2012). These data suggest that patients with familial hyper-
cholesterolemia may benefit from a treatment with specific TH
analogs.
TRβ AGONISTS AND PREVENTION OF HEPATIC STEATOSIS:
SIDE EFFECTS INCLUDING INSULIN RESISTANCE
At first the use of TRβ agonists to ameliorate lipid profiles
was considered unfavorable due to their potential causing, in
analogy with T3, of adipose lipolysis, and induction of hep-
atic lipogenesis and thus steatosis. In fact, T3 poorly reduces
hepatic steatosis in rodent obesity models (Cable et al., 2009).
Genetically obese/diabetic rodent models or models of rodents
placed on high-fat diets have increasingly been used to investi-
gate the efficiency of these compounds to lower lipid profiles and
to counteract non-alcoholic fatty liver disease (NAFLD) (Cable
et al., 2009; Vatner et al., 2012) and hepatic insulin resistance
(Vatner et al., 2012), with varying outcomes.
MB-07811 efficiently reduced hepatic steatosis as well as
plasma FFA and triglycerides in various rodent models includ-
ing male ob/ob mice, male Zucker diabetic fatty (ZDF) rats, and
male C57Bl/6 mice placed on a high-fat rodent diet (60% fat by
kcal) for 3 months. This compound, in contrast to T3, did not
cause adipose lipolysis, and efficiently reduced hepatic steatosis
by inducing hepatic fatty acid oxidation and mitochondrial res-
piration rates, phenomena known to be related to hepatic TR
activation. Unlike T3, MB-07811 did not increase heart weight
and neither did it decrease pituitary thyroid-stimulating hor-
mone beta (TSHβ) expression (Cable et al., 2009). Additional
TRβ agonists, namely GC-1 and KB-2115, tested in similar sys-
tems have proven to be effective in depleting liver lipids, (Cable
et al., 2009; Vatner et al., 2012), but recent evidence has shed
doubt on the potential use of these compounds to ameliorate
insulin sensitivity (Vatner et al., 2012). Male Sprague-Dawley rats
treated daily with GC-1 while being placed on a commercial high-
fat diet showed a 75% reduction of hepatic triglyceride content,
but developed fasting hyperglycemia and hyperinsulinemia due
to increased glucose production and diminished hepatic insulin
sensitivity. In addition, white adipose lipolysis was increased,
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which the authors suggest to contribute to endogenous glucose
production due to the increased glycerol flux (Vatner et al., 2012).
Rats being fed the same diet period but treated daily with KB-2115
displayed a reduction of hepatic steatosis without evident fasting
hyperglycemia, increased glucose production or diminished hep-
atic insulin sensitivity. Instead, insulin-stimulated muscle glucose
uptake was diminished with concomitant reductions in glucose
transporter 4 (GLUT4) protein content (Vatner et al., 2012).
The induction of insulin resistance at various levels by several
TRβ agonists may put their therapeutic potential into question.
Nevertheless, KB-2115 recently entered phase III clinical trials
which were discontinued when cartilage damage was observed in
a long-term study on dogs (Sjouke et al., 2014).
Despite these drawbacks, the need to develop agents that coun-
teract dyslipidemia persists, thus the search for effective TRβ
agonists remains justified. An overview of the metabolic effects
of the described compounds is given in Table 1.
ACTION OF T3 AND OTHER TH METABOLITES BY NOT
DIRECTLY INTERACTING WITH NUCLEAR TR-TREs
In recent years, it has become ever more clear that T3 exerts its
effects not only through nuclear TR-TRE interactions, but also
through cytosolic TRs or even independent of TRs. Ten percent
of the TR pool is localized within the cystosol (Baumann et al.,
2001) and T3 has been shown to interact with these cytosolic TRs
to influence phosphatidyl inositol 3- kinase (PI3K)-Akt signaling,
with phosphorylated Akt subsequently influencing transcription
of genes involved in glucose metabolism via mammalian target of
rapamycin (mTOR) (Moeller et al., 2006). T3-induced phospho-
rylation of Akt in rat skeletal muscle causes glucose transporter 4
(GLUT4) translocation to the sarcolemma (de Lange et al., 2008).
Truncated forms of TRs are also present in mitochondria. A vari-
ant of TRα in mitochondria (Wrutniak-Cabello et al., 2001) has
been suggested to directly stimulate oxidative phosphorylation
upon interaction with T3 (Oetting and Yen, 2007).
Other receptors have been shown to interact with T3: (Davis
et al., 2005). TH interacts with integrin alpha V beta 3 in the
cell membrane. This event triggers the MAPK/ERK pathway with
phosphorylated MAPK translocating into the nucleus and associ-
ating with TRβ (Plow et al., 2000). This causes phosphorylation
of the TRβ receptor, enhancing its action on transcription rate
(Davis et al., 2000). Thus, TR activation can be enhanced through
pathways other than solely TH binding.
Furthermore, T3 causes activation of non-receptor proteins.
AMP-activated kinase (AMPK), which plays a central role in lipid
and glucose metabolism homeostasis (Hardie et al., 2012), has
been shown to be a target of transient and rapid activation (within
hours) by T3 in skeletal muscle (de Lange et al., 2008; Irrcher
et al., 2008). Sirtuins are NAD+ activated deacetylases that have
been shown to play a role in metabolic homeostasis (Chang and
Guarente, 2014). T3 has been shown to activate SIRT1 by various
groups, and this depends on interaction with TRβ (Singh et al.,
2013; Suh et al., 2013; Thakran et al., 2013). Some effects of T3
through SIRT1 require binding of TRβ to TREs (Suh et al., 2013;
Table 1 | From thyromimetics to TRβ ligands and TH metabolites: reported TRβ affinities and metabolic effects.
Ligand Displays TRβ binding
affinity
(with respect to T3)
Reduces Plasma
LDL cholesterol
Acts LDL receptor-
dependent
Prevents hepatic
steatosis
Causes insulin
resistance
Increases heart
weight/rate
THYROMIMETIC
L-94901 Weak Yes No
CGS-23425 Weak Yes No
TRβ AGONIST
GC-1 Equal Yes No Yes Yes No
GC-24 2-fold lower Yes Yes Yes No
KB-141 6-fold lower Yes Yes No
T-0681 Yes Yes No
DITPA Yes Yes No
LIVER-TARGETED
CGH-509A Yes No
MB-07811 Yes Yes No
MB-07344 2-fold lower Yes Yes No
KB-2115 Yes No Yes No
TH METABOLITE
TRIAC 3-fold higher however
no (or weak) TRβ
specificity
No
T1AM None No No Yes No
T2 60-fold lower
(human TRβ) with no
TRβ specificity
Yes No Yes No (rats)
ND (mice)
No/No
(rats)
Yes/ND (mice)*
Abbreviations: ND, not determined; *dose of T2 used in mice is 10-fold higher.
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Thakran et al., 2013). However, one target of T3-TRβ-SIRT1
action is FOXO1, which upon deacetylation triggers the expres-
sion of genes involved in gluconeogenesis in mice that do not
necessarily contain a TRE in their promoters (Singh et al., 2013).
Some of the above mentioned mechanisms of action exerted by
T3 are shared by other THmetabolites. AMPK activation in skele-
tal muscle has been found also to occur by 3,5-diiodo-L-thyronine
(T2) (Lombardi et al., 2009), as well as SIRT1 activation in liver
(de Lange et al., 2011) and in kidney (Shang et al., 2013). These
results have added to the realization that some of the actions of T3
(including those on energy metabolism) can overlap with those
of the TH metabolites with low affinity for TRs. The mechanistic
aspects of the metabolic effects of the thyroid hormone analogs
and metabolites are highlighted in Figure 1.
NATURAL TH METABOLITES, PROMISING LIPID-REDUCING
AGENTS?
Besides T3, the thyroid is a source of other iodothyronines, which
are either produced within the thyroid itself or are deiodinated
periferically, the so-called “non-classical” THs (see for an more
extensive overview Senese et al., 2014). One non-classical TH
with high TR affinity, Triac (3,5,3′-triiodothyroacetic acid), has
been shown to be weakly TRβ-selective and to lower choles-
terol without reduced effects on heart rate (Moreno et al., 2008).
Other TH metabolites, due to their weak binding to TRs, do
not predominantly act through binding to nuclear TRs and by
modulating TRE-mediated gene transcription. An example is
T1AM, an amine present in serum of rodents and humans (Saba
et al., 2010; Hoefig et al., 2011), and in rat liver and brain
(Saba et al., 2010). T1AM has no affinity for TRβ and TRα
(Chiellini et al., 1998). T1AM, however, is a potent agonist of
trace amine-associated receptor 1 (TAAR1), an orphan G protein-
coupled receptor (GPCR) (Zucchi et al., 2006). Contrary to T3,
T1AM does not ameliorate lipid profiles and may cause insulin
resistance depending on the dose: intracerebroventricular (icv)
injection of T1AM into short-term fasted male mice in a dose
of 130 ng/100 gBW (Manni et al., 2012) causes hypophagia as
well as peripheral effects namely raised plasma glucose levels and
reduced peripheral insulin sensitivity despite increased pancreatic
insulin production. This would classify this compound as unsuit-
able for improving metabolic profiles. Another TH metabolite
which has been under study in recent years is T2. This compound
FIGURE 1 | Avenues for regulation of lipid metabolism by thyroid
hormones and analogs. THs may act through transcriptional regulation
by nuclear TR binding but also through interactions involving
cytosolic/mitochondrial TRs or other proteins, each of which influencing
lipid metabolism. For clarity, the TH analogs have not been depicted
separately, negative effects on insulin sensitivity have only been
demonstrated for a subset (see text). Of the thyroid hormone
metabolites only T2 is depicted, since T2 is the only TH metabolite
thus far with low affinity for TRα and positive effects on metabolism.
Avenues are depicted as blue arrows. Dotted arrows: yet to be
determined/confirmed. Effects are depicted as red arrows (negative) or
green arrows (positive).
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has a 60-fold reduced binding capacity to human TRβ (Mendoza
et al., 2013). In line with this, it has been shown that T2 has
a weak transactivating capacity of TRβ target genes in differ-
ent systems, in vitro and in vivo (Ball et al., 1997; Cioffi et al.,
2010; de Lange et al., 2011; Mendoza et al., 2013). Interestingly,
T2 has an affinity for TRβ in fish that is similar to that of T3
(Mendoza et al., 2013), indicating an evolutionary role for this
iodothyronine as a genuine classic TH. In Wistar rats housed
at thermoneutrality and placed on a high-fat diet (50% fat),
T2 (25μg/100 g BW) induces a protein profile favoring a shift
toward fast-twitch, type II skeletal muscle fibers, and a prefer-
ence for glucose as fuel (Moreno et al., 2011). Under the same
conditions, T2 has strong lipid lowering effects and can effec-
tively prevent hepatic steatosis, ameliorating tissue and systemic
insulin sensitivity (de Lange et al., 2011). T2, apart from bind-
ing directly to subunit Va of mitochondrial cytochrome-c oxidase,
enhancing its activity (Arnold et al., 1998), acts by activating hep-
atic nuclear SIRT1, which deacetylates PGC-1α and SREBP-1c,
thus inducing the expression of genes involved in mitochondrial
fatty acid oxidation, and repressing genes involved in lipogen-
esis, respectively, confirmed by proteomic profiling (de Lange
et al., 2011). Thyroid hormones, ameliorating metabolic param-
eters, may improve healthy aging (see for review de Lange et al.,
2013). Indeed, very recently, Padron et al. (2014) reported that T2
administration (25, 50, and 75μg/100 g BW) to aging Wistar rats
reduced body- and retroperitoneal fat mass gain, increased rest-
ing metabolic rate (RMR), ameliorated glucose tolerance, did not
alter heart mass and heart rate, and only lowered serum T4 and
T3 levels at the two higher doses (Padron et al., 2014). A simi-
lar effect was recently observed in HFD-fed mice which showed
increased heart weights only when treated with unusual very high
doses of T2 (250μg/100 g BW) (Jonas et al., 2014). Reaching a
“safe” dose of T2 may thus be feasible in humans as well, which
warrants further investigation.
CONCLUSIONS AND PERSPECTIVES
There has been much progress in identifying “novel” mecha-
nisms of action of T3 and T2 (Figure 1) and TH metabolites and
in developing “safe” (that is: non-thyrotoxic) TH-related com-
pounds to reduce lipid profiles. The discovery of thyroid-related
compounds which could be implied in the regulation of energy
balance may thus pave the way to strategies for their use in the
clinic.
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